Exeporfinium chloride is under clinical development by Destiny Pharma and currently in Phase II for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. According to GlobalData, Phase II drugs for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Exeporfinium chloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Exeporfinium chloride overview

Exeporfinium chloride (XF-73) is under development for the prevention of post-surgical Staphylococcal infections, hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections and Staphylococcal respiratory infections such as hospital and ventilator-associated pneumonia (HVAP) methicillin-resistant S. aureus (MRSA), methicillin-sensitive S. aureus (MSSA), hospital associated-MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA), daptomycin resistant S. aureus, low- and high-level mupirocin-resistant S. aureus, linezolid-resistant MRSA, superficial skin infections caused by bacteria, vancomycin-intermediate S. aureus (VISA), diabetic foot infections, diabetic foot ulcers, oral mucositis and fungal infections such as candidoses. The drug candidate is administered through intranasal route as a gel formulation, topical, oral and inhalation (throat) route. It is a new chemical entity (NCE) and is being developed based on XF platform technology.

Destiny Pharma overview

Destiny Pharma, formerly Destiny Pharma, is a drug development and discovery company. It offers commercial exploitation and clinical development of the antibacterial products. The company provides XF drug platform to address multi drug resistant microbial pathogens that cause infections. Its pipeline products includes NTCD-M3, XF-73 and SPOR-COV. Destiny Pharma’s products find applications for the treatment of clostridioides difficile infections, post surgical infections, dermal infections and COVID-19. The company has its operations through a network of industries, governments and academia. Destiny is headquartered in Brighton, East Sussex, the UK.

For a complete picture of Exeporfinium chloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.